A prospective multicenter trial on sentinel lymph node biopsy
in patients with early-stage cervical cancer (SENTIX)

J 2019

A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX)

CIBULA, D., Ladislav DUŠEK, Jiří JARKOVSKÝ, P. DUNDR, D. QUERLEU et. al.

Základní údaje

Originální název

A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX)

Autoři

CIBULA, D. (203 Česká republika, garant), Ladislav DUŠEK (203 Česká republika, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí), P. DUNDR (203 Česká republika), D. QUERLEU (250 Francie), A. VAN DER ZEE (528 Nizozemské království), A. KUCUKMETIN (826 Velká Británie a Severní Irsko) a R. KOCIAN (203 Česká republika)

Vydání

International Journal of Gynecological Cancer, Philadelphia, Lippincott Williams & Wilkins, 2019, 1048-891X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10103 Statistics and probability

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.095

Kód RIV

RIV/00216224:14110/19:00109664

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1136/ijgc-2018-000010

UT WoS

000459687700030

Klíčová slova anglicky

cervical cancer; sentinel lymph node; pelvic lymphadenectomy; lower leg lymphedema; lymphocele

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 5. 2019 12:39, Soňa Böhmová

Anotace

V originále

Objective Sentinel lymph node (SLN) biopsy has been increasingly used in the management of early-stage cervical cancer. It appears in guidelines as an alternative option to systematic pelvic lymphadenectomy. The evidence about safety is, however, based mostly on retrospective studies, in which SLN was combined with systematic lymphadenectomy. Materials and methods SENTIX is a prospective multicenter trial aiming to prove that less-radical surgery with SLN is non-inferior to treatment with systematic pelvic lymphadenectomy. The primary end point is recurrence rate; the secondary end point is the prevalence of lower-leg lymphedema and symptomatic pelvic lymphocele. The reference recurrence rate was set up conservatively at 7% at 24 months after treatment. With a sample size of 300 patients treated per protocol, the trial is powered to detect a non-inferiority margin of 5% (90% power, p = 0.05) for recurrence rate, 30% reduction in the prevalence of symptomatic lymphocele or lower-leg lymphedema, with reference rates of 30% and 6% at 12 months (p = 0.025, Bonferroni correction). The patients eligible for SENTIX have stage IA1/LVSI+, IA2, IB1 (<2 cm for fertility sparing), with negative LN on pre-operative imaging. Intra-operatively, patients are excluded when there is a failure to detect SLN on both sides of the pelvis in cases of more advanced cancer (stage >IB1), or a positive intra-operative SLN assessment. The quality of SLN pathology evaluation will be assessed by central review. Three interim safety analyses are pre-planned when 30, 60, 150 patients complete 12 months' follow-up. Conclusions The first patient was enrolled into the study in June 2016 and, by June 2018, 340 patients had been enrolled. The first analysis of secondary outcomes should be available in 2019 and the oncological outcome of 300 patients at the end of 2021. The trial is registered as a CEEGOG trial (CEEGOG CX-01), ENGOT trial (ENGOT-Cx 2), and at the ClinicalTrials.gov database (NCT02494063).

Citovat

CIBULA, D., Ladislav DUŠEK, Jiří JARKOVSKÝ, P. DUNDR, D. QUERLEU, A. VAN DER ZEE, A. KUCUKMETIN a R. KOCIAN. A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX). International Journal of Gynecological Cancer. Philadelphia: Lippincott Williams & Wilkins, 2019, roč. 29, č. 1, s. 212-215. ISSN 1048-891X. Dostupné z: https://dx.doi.org/10.1136/ijgc-2018-000010.

@article{1531336,
   author = {Cibula, D. and Dušek, Ladislav and Jarkovský, Jiří and Dundr, P. and Querleu, D. and van der Zee, A. and Kucukmetin, A. and Kocian, R.},
   article_location = {Philadelphia},
   article_number = {1},
   doi = {http://dx.doi.org/10.1136/ijgc-2018-000010},
   keywords = {cervical cancer; sentinel lymph node; pelvic lymphadenectomy; lower leg lymphedema; lymphocele},
   language = {eng},
   issn = {1048-891X},
   journal = {International Journal of Gynecological Cancer},
   title = {A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX)},
   url = {http://dx.doi.org/10.1136/ijgc-2018-000010},
   volume = {29},
   year = {2019}
}

TY  - JOUR
ID  - 1531336
AU  - Cibula, D. - Dušek, Ladislav - Jarkovský, Jiří - Dundr, P. - Querleu, D. - van der Zee, A. - Kucukmetin, A. - Kocian, R.
PY  - 2019
TI  - A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX)
JF  - International Journal of Gynecological Cancer
VL  - 29
IS  - 1
SP  - 212-215
EP  - 212-215
PB  - Lippincott Williams & Wilkins
SN  - 1048891X
KW  - cervical cancer
KW  - sentinel lymph node
KW  - pelvic lymphadenectomy
KW  - lower leg lymphedema
KW  - lymphocele
UR  - http://dx.doi.org/10.1136/ijgc-2018-000010
L2  - http://dx.doi.org/10.1136/ijgc-2018-000010
N2  - Objective Sentinel lymph node (SLN) biopsy has been increasingly used in the management of early-stage cervical cancer. It appears in guidelines as an alternative option to systematic pelvic lymphadenectomy. The evidence about safety is, however, based mostly on retrospective studies, in which SLN was combined with systematic lymphadenectomy. Materials and methods SENTIX is a prospective multicenter trial aiming to prove that less-radical surgery with SLN is non-inferior to treatment with systematic pelvic lymphadenectomy. The primary end point is recurrence rate; the secondary end point is the prevalence of lower-leg lymphedema and symptomatic pelvic lymphocele. The reference recurrence rate was set up conservatively at 7% at 24 months after treatment. With a sample size of 300 patients treated per protocol, the trial is powered to detect a non-inferiority margin of 5% (90% power, p = 0.05) for recurrence rate, 30% reduction in the prevalence of symptomatic lymphocele or lower-leg lymphedema, with reference rates of 30% and 6% at 12 months (p = 0.025, Bonferroni correction). The patients eligible for SENTIX have stage IA1/LVSI+, IA2, IB1 (<2 cm for fertility sparing), with negative LN on pre-operative imaging. Intra-operatively, patients are excluded when there is a failure to detect SLN on both sides of the pelvis in cases of more advanced cancer (stage >IB1), or a positive intra-operative SLN assessment. The quality of SLN pathology evaluation will be assessed by central review. Three interim safety analyses are pre-planned when 30, 60, 150 patients complete 12 months' follow-up. Conclusions The first patient was enrolled into the study in June 2016 and, by June 2018, 340 patients had been enrolled. The first analysis of secondary outcomes should be available in 2019 and the oncological outcome of 300 patients at the end of 2021. The trial is registered as a CEEGOG trial (CEEGOG CX-01), ENGOT trial (ENGOT-Cx 2), and at the ClinicalTrials.gov database (NCT02494063).
ER  -

CIBULA, D., Ladislav DUŠEK, Jiří JARKOVSKÝ, P. DUNDR, D. QUERLEU, A. VAN DER ZEE, A. KUCUKMETIN a R. KOCIAN. A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX). \textit{International Journal of Gynecological Cancer}. Philadelphia: Lippincott Williams \&{} Wilkins, 2019, roč.~29, č.~1, s.~212-215. ISSN~1048-891X. Dostupné z: https://dx.doi.org/10.1136/ijgc-2018-000010.

Podrobný výpis o publikaci